Viholabs - Biotechnology Platform

Viholabs

The Biotechnology Platform That Is Mapping the Gut-Brain Axis to Dominate the Future of Wellness.

The GLP-1 Revolution Created a Void.

99%

of the market seeks a safe, accessible, and sustainable solution that elite drugs cannot offer.

The Hidden
Opportunity

GLP-1 Market ($100B)

Our Solution: Metabolic Synchronization.

The 99% Barrier

Prohibitive Cost

Treatments costing thousands of euros

Adverse Effects

Nausea, fatigue, digestive issues

Invasive Injections

Daily usage barrier

Rebound Effect

Muscle loss and unsustainable results

Viho® Obeglutide Spray

DIRECT SOLUTION

Radical Accessibility

A price for the mass market

Safety and Wellness

Efficacy without adverse effects

Simple Oral Spray

Maximum adherence and ease of use

Real Sustainability

Rebalances the system, doesn't force it

We Don't Sell a Product, We Build a Value Ecosystem.

Our integrated ecosystem connects three strategic pillars that work in synergy to create sustainable value and competitive advantage in the biotechnology market.

VihoLabs AI
Central Platform

Viholabs Lifestyle

Growth Engine and Data

Viholabs Medical

Competitive Moat and High-Value Assets

Continuous Innovation

Rapid Product Launch

Global Traction Today.

YEAR 1 TARGET

6M€

GROSS MARGIN

~67%

ACTIVE MARKET

10 Countries

Our Roadmap to Unicorn Status

Year 1

20 Countries

6M€ Revenue

VihoLabs IA Launch

Year 2

40 Countries

+2 Lifestyle Products

Medical Pipeline Start

Year 3

Scaling

First Medical License Milestone

Year 4

Category Leadership

Profitability

Year 5

+100M€ Revenue

Preparation for Strategic Exit (IPO/M&A)

Financial Projections: The Path to +100M€.

Financial Metrics (€M)

Metric	Year 1	Year 2	Year 3	Year 4	Year 5
Revenue	6	12	25	55	110
Gross Profit	4	8	17	37	74
EBITDA	-0.5	1	3	11	28

Key Assumptions

Growth

Expansion to 40+ countries and annual launch of 2+ new 'Lifestyle' products

Gross Margin

Sustained at ~67% thanks to supply chain optimization

Profitability

Initial investment with scaling to 25% margin in Year 5

The founding alliance that makes the difference

Fernando Rueda

Founder and Chief Strategist

INDUSTRY INSIDER VISION

Co-Architect of Strategies at Novo Nordisk. The only one who can anticipate the market because was there when it was created.

Novo Nordisk

Lluís Vila Prat

Founder and Global Growth Director

GLOBAL EXPANSION ENGINE

30 years of experience bringing health and biotechnology innovations to international markets. The architect of our market dominance.

Global Expansion

Dr. José Luis de Sancho

Founder and Medical-Regulatory Director

REGULATORY NAVIGATOR

Former Director of the Spanish Agency of Health Technologies. Our guarantee of access and compliance in the complex global health landscape.

Regulatory Compliance

The Perfect Storm: The Convergence of Four Unrepeatable Forces.

VIHOLABS

1. THE MARKET TSUNAMI

GLP-1s created a 100,000M€ wave and educated the world, but can only serve 1%. We're the only company designed to absorb the 99% of this massive and validated demand.

2. THE PIONEER ADVANTAGE

We're the first to launch a holistic, safe, and accessible metabolic control solution at global scale. The market is educated, desperate, and without alternatives. Our window to capture leadership is NOW.

3. THE TECHNOLOGY MULTIPLIER

Our AI ecosystem doesn't just create products; it converts today's revenue into a data moat and Intellectual Property for the future. This is our valuation multiplier.

4. THE "INSIDER" TEAM

With a team that was inside the mind of Novo Nordisk, we don't have to guess the market's future; we come from it. This is our unassailable credibility.

We Request 5M€ to Dominate the Market.

Capital to execute a proven plan and scale our global platform.

5M€
Strategic investment to accelerate our growth and consolidate leadership

Execution of validated plan with global traction

Rapid scaling of operations in 40+ countries

Boost to innovation in AI platform

Marketing and Brand (40%)

Team Expansion (25%)

R&D and AI Platform (15%)

International Expansion (15%)

Working Capital (5%)

Thank You

Join us in revolutionizing metabolic wellness and capturing the 99% market opportunity

Let's Connect

info@viholabs.com